HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nearly 9% FY 2019 Increase For FDA In Shutdown-Averting Appropriations Bill

Executive Summary

Consolidated Appropriations Act gives FDA $5.58bn overall, 8.7% more than allocated in FY 2018. FDA received $268.8m in additional budget authority and $178.3m in additional user fee funds. FY 2019 funding would have lapsed Feb. 16 and another government shutdown would have started if President Trump didn't sign the bill on Feb. 15.

You may also be interested in...



HBW Legislative News: Another Federal CR, Michigan On DXM List, Senators Say Supplements Are 'Medical Expenses'

Federal agencies at FY 2019 funding for another month; Michigan imposes age restriction on OTC DXM sales; and senators urge IRS to make supplements 'medical expenses'.

No Shutdown But Funding Lower Than House Bill In US FDA Budget Forecast

Former Senate Appropriations Committee staffer expects FDA's FY 2020 budget will not be finalized until early next year and that it will be close to the sum in the appropriations bill passed by the Senate.

House Appropriators Propose OTC Monograph User Fee In FDA Budget

Nearly $263.4m in additional funding compared to previous fiscal year's total allocated to FDA in the House appropriations bill. More than 70% of increase, about $185.3m, would be in non-user fees or budget authority and $78.1m in would come from user fee revenue. Bill identifies an additional user fee program for agency in the event Congress passes legislation to overhaul FDA's OTC drug monograph process.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel